STAT3 and prostate adenocarcinoma: The PFS of patients with LGG (Figure 2e), HNSC (Figure 2f), SKCM (Figure 2g), prostate adenocarcinoma (PRAD) (Figure 2h), and colon adenocarcinoma (COAD) (Figure 2i) was significantly different, and the PFS of the low STAT3 expression group was significantly higher than that of the high expression group in LGG.